Atai Life Sciences N.V. (ATAI)

Market Cap	440.74M
Revenue (ttm)	1.86M
Net Income (ttm)	-148.99M
Shares Out	200.34M
EPS (ttm)	-0.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,419,979
Open	2.115
Previous Close	2.060
Day's Range	2.090 - 2.265
52-Week Range	1.030 - 2.565
Beta	1.22
Analysts	Strong Buy
Price Target	10.50 (+377.27%)
Earnings Date	May 14, 2025

About ATAI

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with sc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 18, 2021
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: ATAI
• Website: https://atai.com

Financial Performance

In 2024, Atai Life Sciences's revenue was $308,000, a decrease of -1.91% compared to the previous year's $314,000. Losses were -$149.27 million, 271.1% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 377.27% from the latest price.

Price Target

$10.5

(377.27% upside)

Analyst Consensus: Strong Buy